{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Monopar Therapeutics Hits New 52-Week High at $68.18
Monopar Therapeutics, Inc. has achieved a new 52-week high of USD 68.18, significantly up from its low of USD 3.90. With a market capitalization of USD 256 million, the company operates in the Pharmaceuticals & Biotechnology sector, facing challenges reflected in its financial metrics.
Monopar Therapeutics Stock Soars to New 52-Week High of $58.94
Monopar Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. With a market capitalization of USD 256 million, the company operates at a loss and has a unique financial structure, highlighting its evolving position in the biotechnology sector.
Monopar Therapeutics Hits New 52-Week High of $54.54
Monopar Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. Operating in the Pharmaceuticals & Biotechnology sector, the company has a market capitalization of USD 256 million, though it faces challenges with negative financial metrics and a premium price-to-book ratio.
Is Monopar Therapeutics, Inc. technically bullish or bearish?
As of June 2, 2025, Monopar Therapeutics, Inc. shows a mildly bullish trend based on daily moving averages and monthly indicators, despite some short-term bearish signals from the weekly MACD and KST.
What does Monopar Therapeutics, Inc. do?
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing cancer therapeutics, with a market cap of approximately $208.53 million and a recent net profit of -$3 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap firm.
How big is Monopar Therapeutics, Inc.?
As of Jun 18, Monopar Therapeutics, Inc. has a market capitalization of 208.53 million, with net sales of 0.00 million and a net profit of -16.57 million over the latest four quarters. The company reported shareholder's funds of 55.04 million and total assets of 60.29 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
